AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Return on equity
AbbVie Inc.'s return on equity over the twelve months to 30 June 2026 was −208.1%, down 6364.0 percentage points from fiscal 2025 (6,155.9%). Over the past ten years it has ranged from −339.6% (fiscal 2018) to 6,155.9% (fiscal 2025) — the current reading is the highest in ten years. That is below the Drug Manufacturers General industry median of 5.87% and below the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 6,155.9% | 6,094.29 |
| FY2024 | 61.6% | 26.77 |
| FY2023 | 34.8% | (37.19) |
| FY2022 | 72.0% | (8.89) |
| FY2021 | 80.9% | (106.55) |
| FY2020 | 187.5% | 282.31 |
| FY2019 | −94.9% | 244.76 |
| FY2018 | −339.6% | (448.71) |
| FY2017 | 109.1% | (29.66) |
| FY2016 | 138.8% | (42.15) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LLY Eli Lilly and Company compare | 102.3% |
| AMGN Amgen Inc. compare | 91.5% |
| NVS Novartis AG compare | 30.4% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. compare | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| JNJ Johnson & Johnson compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. | −208.1% |
| Drug Manufacturers General industry median | 5.87% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ABBV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement